AMYT News and Press, Amryt Pharma plc

Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...

Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...

2023-04-11 07:56:33 ET Summary Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 milestones that pay out $1 and $1.50 on certain conditions. Today is likely the final day the stock...

High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...

2023-03-22 11:55:01 ET Amryt Pharma ( NASDAQ: AMYT ) shareholders have approved the company's acquisition by Chiesi Farmaceutici. The deal is expected to close in Q2. Although the waiting period under the Hart-Scott-Rodino Antitrust Act has ended, the transaction is ...

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 2 2 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutic...

A MRYT P UBLISHES SCHEME CIRCULAR A ND ANNOUNCES T HE SHAREHOLDER MEETINGS T O CONSIDER A ND VOTE O N T HE CHIESI ACQUISITION W ILL B E H ELD O N MARCH 22, 2023 Dublin, Ireland, February 1 ...

Summary I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter. I just am not sure if I should be buying Krystal Biotech at current prices, given certain issues I discuss. Krystal Biotech ( KRYS ) has ...

Shares of Amryt Pharma (NASDAQ: AMYT) were up 109.4% for the week, as of Thursday afternoon, according to S&P Global Market Intelligence . Shares of the Irish commercial-stage biopharmaceutical company, which specializes in rare and orphan diseases, closed last Friday at $7 a shar...

Summary Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones. Amryt Pharma achieved its sales target in the highly competitive market for rare disease the...